SEC Form 4 · accession 0001209191-17-010165
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gad Soffer
Officer — EVP & Chief Strategy Officer
Period of report
Feb 10, 2017
Accepted (ET)
Feb 13, 2017 · 6:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3 | Feb 10, 2017 | S | 5,874 | $15.42 | D | 269,938 | D | |
| Common StockF4 | Feb 10, 2017 | S | 400 | $16.13 | D | 269,538 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016.
- F2Shares sold to cover tax liability from settlement of RSUs.
- F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.00 to $16.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.